A technical view., page-33

Where is the trial currently at?
ASX Listing Rules 3.1 and 3.1A. These rules provide: 3.1 Once an entity is or becomes aware of any information concerning it that a reasonable person would expect to have a material effect on the price or value of the entity’s securities, the entity must immediately tell ASX that information.
3.1A Listing rule 3.1 does not apply to particular information while each of the following requirements is satisfied in relation to the information:
3.1A.1 One or more of the following 5 situations applies: · It would be a breach of a law to disclose the information; · The information concerns an incomplete proposal or negotiation; · The information comprises matters of supposition or is insufficiently definite to warrant disclosure; and others
http://www.asx.com.au/documents/about/abridged-continuous-disclosure-guide-clean-copy.pdf
So what would a reasonable person expect to affect the sp?
1) Incidence of treatment-emergent adverse events [ Time Frame: Day 0 to Day 56 ]
To be evaluated by the number, duration and severity of treatment emergent adverse events (AEs).
2) Recommended Phase 2 Dose (RP2D) [ Time Frame: Day 0 to Day 56 ]
To be evaluated by safety/tolerability and immunogenicity data for IMU-131 (P467-specific antibodies (IgG) and Her-2- specific antibodies (IgG) titers).

So what can a reasonable person (me) reasonably conclude from the veil of silence that prevails?
1) Dosing has started (we know that much) but the proposed level of recruitment (6) for the low dose cohort has not yet been achieved (IMO this should be disclosed)… let alone for Cohorts 2 and 3
or
2) Dosing of the fully enrolled low dose cohort has not been completed and outcome not yet assessed (IMO this does not need to be disclosed)
or
3) Dosing of the full low dose cohort has been completed and outcome has been assessed (IMO this should be disclosed)
Unless IMU have breached the disclosure laws then I can’t see how there can be any significant announcements in relation to progress on the IMU -131 trial at the AGM or the meeting of experts.